revenu million
valu usd unless otherwis note
strength cf franchis build
view report strong driven orkambi uptak younger
pt continu symdeko growth lead top-lin beat even
adjust inventori contribut solid cf product uptak tripl
combo larg de-risk out-year sale expans pipelin asset
track see low-risk year set compani best-in-
class long-term growth estim ep compound-annual-growth-rate margin
though increasingli reflect valuat see continu share upsid
potenti given scarciti valu high-qual long-term growth name
limit clinic competit ip risk adjust pt
strong revenu driven symdeko growth orkambi resili
underscor cf franchis strength strong uptak orkambi
recent approv popul off-set continu
cannib symdeko led q-o-q increas
well consensu estim addit symdeko
growth continu q-o-q kalydeco
line estim lead top-lin beat even without
benefit inventori build cf revenu would still
line estim vs forecast
well consensu rel in-lin opex vs
consensu show continu good expens control help
drive continu oper margin expans lead above-consensu
non-gaap ep
conserv guidanc leav opportun upsid expect
sale guidanc includ anticip revenu
geographi cf medicin alreadi approv includ
label assumpt approv symdeko
old view highli like momentum symdeko adult
orkambi young children potenti reimburs progress
possibl earlier-than-expect tripl combo approv see good
possibl upsid guidanc street consensu rev
estim seem overli concern risk
ip revoc uk garner recent attent
listen hous common debat yesterday
announc receipt prv increment upsid surpris
potenti valu estim
major pipelin updat expect see addit de-risk tripl
diversif progress data remain track
longer follow-up data tripl year given histor data
see low risk major dropoff given good pt retent
see low risk unexpect emerg longer dose
continu page
price prior trade day market close estimate unless otherwis note
bullish prospect cf tripl combo
come recent data program progress
particularli concern long-term threat franchis
given high bar limit potenti competitor
believ high growth prospect estim
ep compound-annual-growth-rate potenti best-in-class margin confer
scarciti valu though share bake optim
outstand initi data tripl combo set high
bar may difficult surpass believ given
compani strong fundament addit appreci
beyond broader biotech tape like
posit leader high-growth high-margin cf space
led kalydeco orkambi symdeko promis tripl
combo cf data could expand cf opportun high bar
potenti futur competitor
risk price pressur competit entrant could
outsiz neg impact out-year revenu next
gen corrector set initi ph iii trial though still
complet derisk safeti difficult improv
upon initi data addit tripl combo result
submiss nda tripl combo fda
data studi post-op acut
bunionectomi pain addit updat ex-
 reimburs approv therapi
bloomberg capit market estim upside/downside/target
base case assum probabl success
expans het/min improv persistence/compli
tez/iva introduct tez/iva price blend current
kalydeco orkambi price price target deriv
dcf analysi discount rate
success tripl combo enabl expans het/min cf
patient better expect tez/iva and/or ex-u price
power higher complianc improv would lead
upsid estim upsid scenario potenti
dcf-base valuat would
failur tripl combo emerg competit reduc
long-term market share erod price power would lead
downsid estim downsid scenario
potenti dcf-base valuat would
continu page
continu guid nda expect rapid approv estim
increment sale start otherwis materi pipelin
ph iib dose-rang studi fulli enrol program remain track
one asset clinic anoth enter initi ph i/ii trial
scd b-thaland note manag express continu interest
potenti bd focus earlier-stag asset add valu clinic
develop regulatori commerci expertis
exhibit potenti mileston pipelin
producteventtimelinepotenti reimburs franc phase studi infant year studi children cf age tripl combo ph nda tripl combo tripl combo poc studi addit next-gen studi post-op acut bunionectomi ph studi small fiber inhibitoradv clinic deuter ivacaftor ph ii dose-rang monotherapi ph i/ii ex-u studi ph lead corrector corrector enter clinic fibrosi gate residu function mutationsmarketedorkambicyst fibrosi homozygousmarketedtez/iva symdeko/symkevi cystic fibrosi corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase formerli fibrosi homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase ciliari dyskinesiaphas spinal cord injuryphas tumorsphas crispr beta-thalassemia sickl cell diseasephas i/ii enter fibrosisent ph ismall-molecul corrector antitrypsin defici enter ph iaddit inhibitorspainpreclinicalearli pipelinefoc segment glomerulosclerosispreclinicaldrug/target orkambimilestonesnext-gen corrector exhibit incom statement
thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand biotechnolog
price target deriv dcf analysi base busi discount
rate termin growth rate price target support outperform rate
risk rate price target
risk includ lower expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
global biotechnolog compani focus develop
small molecul drug seriou unmet diseas compani previous develop
drug fda approv hiv hep multipl approv drug
includ kalydeco orkambi symdeko treatment variou mutat cystic
fibrosi develop pipelin addit cf drug popul
current drug address addit vertex work build pipelin
beyond cf next year vertex aspir becom fulli integr
biopharmaceut compani discoveri commerci global sale
market commerci infrastructur
